APD 371

Drug Profile

APD 371

Alternative Names: APD-371

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator Arena Pharmaceuticals
  • Class Analgesics
  • Mechanism of Action Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pain

Most Recent Events

  • 18 May 2017 Phase-II clinical trials in Pain in USA (PO) (NCT03155945)
  • 08 Aug 2016 APD 371 is still in phase I trials for Pain in USA
  • 08 Aug 2016 Arena Pharmaceuticals plans a phase II trial for Pain associated with Crohn's disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top